Free Trial
→ A free stock pick, from me to you (From Behind the Markets) (Ad)tc pixel
NASDAQ:EPRX

Eupraxia Pharmaceuticals Q3 2026 Earnings Date & Estimates

Eupraxia Pharmaceuticals logo
$7.45 +0.03 (+0.40%)
As of 02:17 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Eupraxia Pharmaceuticals is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026, before market opens.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Eupraxia Pharmaceuticals in Q3 2026

Eupraxia Pharmaceuticals is expected to post earnings of -$0.26 per share. In the same quarter a year earlier Eupraxia Pharmaceuticals reported -$0.19 per share. Eupraxia Pharmaceuticals last reported on August 11, 2026, posting -$0.23 per share and beating the -$0.25 consensus estimate. Eupraxia Pharmaceuticals has beaten the consensus EPS estimate in 2 of its last 7 quarters.

Consensus Estimates

Consensus EPS
-$0.26
Prior-Year EPS
-$0.19

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.23 (Beat by +$0.02)
EPS Beat Rate
2 of last 7 quarters

Prepare for the Q3 2026 Call

Eupraxia Pharmaceuticals Q3 2026 Earnings FAQ

Eupraxia Pharmaceuticals (NASDAQ:EPRX) is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Eupraxia Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Thursday, November 19, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Eupraxia Pharmaceuticals to post earnings of -$0.26 per share for Q3 2026.

Eupraxia Pharmaceuticals Earnings Headlines

Eupraxia Pharmaceuticals (EPRX) Has a New Rating from RBC Capital
November 10 at 8:13 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/EPRX-Q/pressreleases/8752017/eupraxia-pharmaceuticals-eprx-has-a-new-rating-from-rbc-capital/
RBC Initiates Eupraxia Pharmaceuticals at Outperform, Speculative Risk With $14 Price Target
November 9 at 5:07 PM  |  marketscreener.comM
The warning signs most investors see too late
Dr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. Now, after 55 years of market analysis, he says conditions are forming for a financial crisis that could rival or exceed 2008.tc pixel
November 10 at 1:00 AM  |  Weiss Ratings (Ad)
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Cut to "Strong Sell" at Wall Street Zen
November 8 at 1:07 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31184700
Eupraxia Pharmaceuticals (EPRX) Stock Forecast & Price Target
November 4, 2026  |  tipranks.comhttps://www.tipranks.com/stocks/tse:eprx/forecast
Eupraxia Pharmaceuticals (EPRX) Projected to Post Earnings on Tuesday
November 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31173324
See More Eupraxia Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eupraxia Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eupraxia Pharmaceuticals and other key companies, straight to your email.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals (NASDAQ:EPRX) is a Canadian clinical-stage biopharmaceutical company focused on developing locally delivered therapies for chronic diseases. The company uses its proprietary DiffuSphere technology to formulate drug products designed to provide controlled, sustained release at targeted sites in the body, with the goal of improving treatment effectiveness and tolerability.

Eupraxia’s lead development program, EP-262, is an intra-articular therapy being developed for osteoarthritis of the knee. The company’s research has also included locally delivered treatments for gastrointestinal and other inflammatory conditions, including programs designed to address ulcerative colitis and related diseases.

Founded in 2011 and headquartered in Victoria, British Columbia, Eupraxia conducts research and clinical development activities through international collaborations and clinical programs. Its shares trade on the Nasdaq Capital Market under the symbol EPRX.

View Eupraxia Pharmaceuticals Profile
Earnings Tools